Millipore to buy Serologics for $1.4B
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Millipore |
Serologicals |
$1.4B buyout |
Serologicals commercializes technologies for manufacturing biologics and Millipore is a biosciences products company. |
|
Bruker BioSciences |
Bruker Optics |
$135 buyout |
Bruker Biosciences will buy Bruker Optics for $135 million in cash and stock. Both companies are majority-owned by five members of the Laukien family. |
|
Fisher Scientific International |
Clintrak Pharmaceutical Services |
$125M buyout |
Clintrak provides clinical trial printing services. |
|
YM Biosciences |
Eximias Pharmaceutical |
$25M buyout |
YM BioSciences is acquiring Eximias Pharmaceutical in a part-cash, part-stock deal. The full value of the acquisition was not disclosed. |
|
Alteon |
HaptoGuard |
$8.8M buyout |
The companies both have products for cardiovascular diseases, diabetes and other inflammatory diseases. |
|
SRI International |
Quality Clinical Labs |
Buyout |
QCL specializes in clinical hematology and chemistry evaluations and has about 50 biotech clients in the San Francisco Bay area. |
|
Pfizer |
Schwarz Pharma |
$210M licensing deal |
Schwarz has license its drug for overactive bladder to Pfizer. The company will gain a $100 million up-front payment and up to $110 million more in milestones. |
|
Chemokine Therapeutics |
Pharmaceutical Product Development |
$2.5M licensing deal |
Chemokine is reacquiring the licensing rights to CTCE-0214, which it granted to PPD in April 2003. |
|
GSK |
Japan Tobacco |
Licensing deal |
The deal is for the worldwide rights to a preclinical compound developed by Japan Tobacco. |
|
ImQuest Pharmaceuticals |
Samjin Pharmaceutical |
Licensing deal |
ImQuest has licensed the Piperazine Series of anti-cancer therapeutic compounds from Samjin. |
|
ImQuest Pharmaceuticals |
Isis Pharmaceuticals |
Licensing deal |
Isis has licensed its topical HIV therapy, Isis 5320, to ImQuest. |
|
Athenagen |
Osprey |
Assets acquisition |
Athenagen gains Osprey's lead drug candidate for Alzheimer's. Athenagen also nets a large library of analogs in the deal. |
|
Lectus Therapeutics |
NeuroServe |
Asset acquisition |
NeuroServe is an electrophysiology company which tests compounds on ion channels for pharmaceutical and biotech clients. |
|
Future Systems |
Rexahn |
$35M sale |
Rexahn agreed to sell regional sales rights to three of its experimental drugs to Korea's Future systems for $35.8 million while agreeing to buy $35 million in the company's stock. |
|
Amgen |
Alcon Collaboration |
Collaboration |
The companies will research, develop and commercialize therapeutics to treat eye diseases. Terms of the deal were not disclosed. |
|
MedImmune |
Elusys Therapeutics |
Collaboration |
The companies will collaborate to develop new therapies for infectious diseases. Details of the deal were not released. |
|
Asuragen |
Digene |
Marketing deal |
The companies have struck deal for the worldwide marketing and distribution of Asuragen's cystic fibrosis screening products. |
|
Gilead |
Corus |
$25M investment |
Gilead will become second-largest investor in Corus, a private biotech company that's been developing candidates for respiratory and infectious diseases. |